Volver

Tonix Pharmaceuticals Holding Corp

Ticker: TNXP ISIN: US8902608392
Añadir al portafolio Análisis de cartera en 2min
Stock Small-cap High beta
Capitalización
190,19 M $
P/E
0,06
Forward P/E
0,00
Profit margin
0,00%
Revenue growth QoQ
16,60%
Beta
1,82
13,64 $ -0,15%
Precio a fecha de 2026-08-26 · NASDAQ

Rendimiento por período

Rendimientos acumulados
1 Month +37,22%
6 Months -5,47%
1 Year -57,61%
5 Years -87,49% p.a.-100,00%
10 Years -67,41% p.a.-100,00%
Since inception -53,67% p.a.-100,00%
Rendimientos por año
YTD -12,68%
2025 -52,67%
2024 -97,42%
2023 -83,59%
2022 -96,61%
2021 -47,06%

Key stats

Market cap
190,19 M
P/E
0,06
Beta
1,82
52-week range
6.76 - 72.00
50-day MA
22,34
200-day MA
26,61
Section 1

Business overview

Company profile data from fundamentals.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.

Sector Healthcare
Industry Biotechnology
Country United States
Exchange NASDAQ
Section 2

Financial quality

Above-average volatility

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -64,99%
ROA -35,94%
Profit margin 0,00%
Operating margin -10,05%
PEG ratio 0,00
Revenue/share TTM 1,68
Revenue TTM 10,30 M
EBITDA -97,46 M
Gross profit TTM 3,53 M
Beta 1,82

Valuation

Trailing P/E 0,06
Forward P/E 0,00
P/B 0,98
P/S 22,05
EV/EBITDA 0,94
EV/Revenue 3,63
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) -10,30
Quarterly earnings growth 0,00%
Revenue TTM 10,30 M
Reported quarters 55
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0,00%
Split factor 1:100
Last split date 2025-02-05
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 67,67 $
Analyst rating 5

Ownership & short interest

Shares outstanding 11,78 M
Shares float 11,77 M
Institutional ownership 17,79%
Insider ownership 3,40%
Short ratio 2,19
Short % of float 15,99%

Details

Instrument metadata and source update timestamps.

Symbol TNXP
Name Tonix Pharmaceuticals Holding Corp
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US8902608392
Country USA
Code + exchange TNXP.NASDAQ
Fundamentals updated 2025-12-16

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.